Arash Rassoulpour
Overview
Explore the profile of Arash Rassoulpour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Creed R, Menalled L, Casey B, Dave K, Janssens H, Veinbergs I, et al.
Neuroscience
. 2019 Apr;
409:169-179.
PMID: 31029729
Parkinson's disease (PD) is the most common neurodegenerative movement disorder and is characterized by the loss of neurons in the substantia nigra that project to the striatum and release dopamine...
2.
Groessl F, Munsch T, Meis S, Griessner J, Kaczanowska J, Pliota P, et al.
Nat Neurosci
. 2018 Jun;
21(7):952-962.
PMID: 29950668
Functional neuroanatomy of Pavlovian fear has identified neuronal circuits and synapses associating conditioned stimuli with aversive events. Hebbian plasticity within these networks requires additional reinforcement to store particularly salient experiences...
3.
DeKorver N, Lichty D, van der Hart M, Rassoulpour A, Bonasera S
Matters (Zur)
. 2017 Sep;
2017.
PMID: 28894740
Mobility and locomotor impairments have high prevalence, morbidity, and significant mortality in older adult populations. Cerebellar functional changes have been implicated in the pathogenesis of these age-related mobility and gait...
4.
Woodling N, Colas D, Wang Q, Minhas P, Panchal M, Liang X, et al.
Brain
. 2016 May;
139(Pt 7):2063-81.
PMID: 27190010
Identifying preventive targets for Alzheimer's disease is a central challenge of modern medicine. Non-steroidal anti-inflammatory drugs, which inhibit the cyclooxygenase enzymes COX-1 and COX-2, reduce the risk of developing Alzheimer's...
5.
Beaumont V, Mrzljak L, Dijkman U, Freije R, Heins M, Rassoulpour A, et al.
Exp Neurol
. 2016 May;
282:99-118.
PMID: 27163548
Dysregulation of the kynurenine (Kyn) pathway has been associated with the progression of Huntington's disease (HD). In particular, elevated levels of the kynurenine metabolites 3-hydroxy kynurenine (3-OH-Kyn) and quinolinic acid...
6.
Toledo-Sherman L, Prime M, Mrzljak L, Beconi M, Beresford A, Brookfield F, et al.
J Med Chem
. 2015 Jan;
58(3):1159-83.
PMID: 25590515
We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for...
7.
Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, et al.
PLoS Curr
. 2014 Feb;
6.
PMID: 24558637
Huntington's disease is a neurodegenerative disorder caused by mutations in the CAG tract of huntingtin. Several studies in HD cellular and rodent systems have identified disturbances in cyclic nucleotide signaling,...
8.
Zwilling D, Huang S, Sathyasaikumar K, Notarangelo F, Guidetti P, Wu H, et al.
Cell
. 2011 Jun;
145(6):863-74.
PMID: 21640374
Metabolites in the kynurenine pathway, generated by tryptophan degradation, are thought to play an important role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases. In these disorders, glutamate receptor-mediated excitotoxicity...
9.
Sathyasaikumar K, Stachowski E, Wonodi I, Roberts R, Rassoulpour A, McMahon R, et al.
Schizophr Bull
. 2010 Nov;
37(6):1147-56.
PMID: 21036897
The levels of kynurenic acid (KYNA), an astrocyte-derived metabolite of the branched kynurenine pathway (KP) of tryptophan degradation and antagonist of α7 nicotinic acetylcholine and N-methyl-D-aspartate receptors, are elevated in...
10.
Gregoire L, Rassoulpour A, Guidetti P, Samadi P, Bedard P, Izzo E, et al.
Behav Brain Res
. 2007 Sep;
186(2):161-7.
PMID: 17868931
Increased glutamatergic activity is believed to play a significant role in the development of levodopa-induced dyskinesias (LID). LID may therefore be attenuated by a reduction in glutamatergic function. This was...